​

Funding Round

Series C - Checkmate Pharmaceuticals

Series C - Checkmate Pharmaceuticals

Investment Firm

Overview

Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.

Announced Date

Jun 10, 2020

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

Novo Holdings

Novo Holdings

Novo Holdings is a debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and secondary_market and seed and venture firm.

Longitude Capital

Longitude Capital

Longitude Capital is a debt and early_stage_venture and late_stage_venture and private_equity and venture firm.

Participant Investors

11

Investor Name
Participant InvestorNovo Holdings
Participant InvestorMedicxi
Participant InvestorF-Prime Capital
Participant InvestorClough Capital Partners
Participant InvestorOmega Funds

Round Details and Background

Checkmate Pharmaceuticals raised $85000000 on 2020-06-10 in Series C

Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 27, 2020
Venture Round - Checkmate Pharmaceuticals
-16.0M
Jun 10, 2020
Series C - Checkmate Pharmaceuticals
11-85.0M
Jun 15, 2017
Series B - Checkmate Pharmaceuticals
5-27.0M
Aug 12, 2015
Series A - Checkmate Pharmaceuticals
2-20.0M

Recent Activity

There is no recent news or activity for this profile.